Bioregulators & Organ Support
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Morning
Receptor / target
Cerebral Cortex
Properties
Not listed
Pre-mixed
No
Cortagen
← Back to Library
Protocol not independently verified Neural Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Cortagen is reviewed here for organ-support and bioregulator research.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Organ-support research, Tissue signaling
Mechanism
Target context: Cerebral Cortex
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Morning
Receptor / target
Cerebral Cortex
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily | Take upon waking. |
| Weeks 3-4 | 2mg 1x Daily | Take upon waking. Repeat every 6 months. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1: Extended Protocol (Goal: general cortical aging normalization with minimized peak concentration variability; preferred for sensitive subjects)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg daily upon waking | Smoother absorption profile. Lower daily peak than 10-day 10mg course with broader time-exposure profile. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2: Cognitive Performance Optimization Protocol (Goal: peak cognitive output enhancement for high-demand intellectual work periods; time cycle to coincide with critical project phases)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 1mg 1x Daily upon waking | Ramp phase. Cortical activation enhancement begins accumulating. |
| Days 6-14 | 2mg 1x Daily upon waking | Full dose. Time the peak cycle to coincide with highest-demand cognitive work. |
| Days 15-28 | 2mg 1x Daily upon waking | Extended maintenance phase for sustained cognitive enhancement through the work period. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 3: Post-Stroke or TBI Cortical Recovery Protocol (Goal: cortical neuroplasticity and synaptic density restoration following ischemic stroke or traumatic brain injury; minimum 6 weeks post-event, neurologist clearance required)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500 mcg 1x Daily upon waking | Conservative entry. Requires neurologist clearance. Minimum 6 weeks post-acute neurological event. |
| Weeks 3-4 | 1mg 1x Daily upon waking | |
| Weeks 5-8 | 2mg 1x Daily upon waking | Full therapeutic dose. Run concurrently with Cerebrolysin for maximal neurotrophic support. |
| Weeks 9-12 | 2mg 1x Daily upon waking | Extended cycle appropriate for stroke/TBI recovery context. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 4: Early Neurodegeneration Intervention Protocol (Goal: early-stage MCI or vascular dementia: cortical bioregulator support combined with Pinealon + Cerebrolysin triple CNS stack; neurologist supervision)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-3 | 500 mcg 1x Daily upon waking | Entry dose. Run Pinealon concurrently at its standard dose. Stagger Cerebrolysin to begin on Day 5. |
| Days 4-10 | 1mg 1x Daily upon waking | |
| Days 11-20 | 2mg 1x Daily upon waking | Full combined CNS stack at target doses. Assess cognitive function markers at day 20 baseline and 60-day follow-up. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 5: Seasonal Cognitive Maintenance Protocol (Goal: twice-yearly cortical bioregulator support for healthy aging subjects; biannual schedule)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 (Q1) | 1mg 1x Daily upon waking | Cycle 1 ramp. |
| Weeks 3-4 (Q1) | 2mg 1x Daily upon waking | Cycle 1 full dose. |
| Weeks 1-2 (Q3) | 1mg 1x Daily upon waking | Cycle 2 ramp. ~6-month separation produces consistent cortical bioregulator exposure across the year. |
| Weeks 3-4 (Q3) | 2mg 1x Daily upon waking | Cycle 2 full dose. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older, regional, or weakly indexed evidence. Entry context: target (Cerebral Cortex); route Subcutaneous; timing Morning. Unapproved or unverified dosing examples are hypotheses, not recommendations.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in organ-specific peptide-bioregulator literature, often with older regional clinical reports plus preclinical or mechanistic studies. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Cerebral Cortex. Route(s): Subcutaneous. Dosing window on page: Morning. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Bioregulator entries commonly rely on organ-specific peptide literature with variable indexing and older clinical traditions.
- Treat organ-system claims cautiously unless they are supported by modern, indication-specific clinical trials or labels.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-2, 1mg 1x Daily; Alternative Titration 1: Extended Protocol (Goal: general cortical aging normalization with minimized peak concentration variability; preferred for sensitive subjects): Days 1-20, 5mg daily upon waking.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor organ-specific labs, autoimmune/transplant context, cancer history, and the age/quality of the cited literature.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active seizure disorders not under pharmacological control: cortical bioregulator activity affecting neuronal excitability and synaptic signaling has not been evaluated in subjects with uncontrolled epilepsy; any compound affecting cortical neuronal gene programs in the context of pathological hyperexcitability warrants medical supervision.
- Active CNS infection (meningitis, encephalitis): exogenous cortical bioregulator activity during active brain infection could interfere with the CNS immune response and neuroinflammatory defense mechanisms.
- Concurrent use with CNS-active medications requiring stable plasma levels (narrow therapeutic index antiepileptics, MAOIs, lithium): while no direct pharmacokinetic interactions are documented, any compound affecting neuronal function in subjects on narrow-index CNS drugs warrants awareness.
- Known hypersensitivity to Cortagen (Ala-Glu-Asp-Pro tetrapeptide) or formulation excipients.
- Pregnancy: cortical neurodevelopmental processes during fetal brain formation are tightly regulated; exogenous cortical bioregulator activity has not been characterized during fetal CNS development.
- Severe psychiatric disorders in acute phase (psychosis, severe mania): cortical gene program modulation in subjects with acute cortical dysregulation from psychiatric disease may produce unpredictable effects.
- Active malignant brain tumors: bioregulator normalization of cortical cell gene programs in the context of CNS malignancy where tumor cells may express cortical tissue receptors has not been characterized.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Increased dream vividness: the cortical activation enhancement from Cortagen in the morning can produce increased REM activity in subsequent sleep; some subjects report more vivid and memorable dreams during Cortagen cycles.
- Mild headache on cycle initiation: uncommonly reported in the first 1-3 days as cortical metabolic activity normalizes; typically self-limiting.
- Increased energy and alertness: a commonly reported desired effect rather than an adverse event; the morning dosing timing is designed to leverage this cortical activation enhancement for daytime cognitive performance.
- Mild mood elevation: the improvements in cortical BDNF-pathway-related neuroplasticity mechanisms can produce subjective mood brightening; typically mild and within the normal range.
- Potential overstimulation in sensitive subjects: subjects who are already highly cognitively activated (high-stress periods, concurrent stimulant use) may find the cortical activation effects of Cortagen amplifying to an uncomfortable degree; managed by dose reduction or timing adjustment.
- Injection site mild reaction: standard subcutaneous peptide response.
- No serious neurological adverse events documented in the Khavinson research literature: Cortagen's published safety profile across aging and neurological disease research populations is clean at standard protocol doses.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.